Latest news for health care topics. Include medical news , health insurance , therapy and vaccine news

Friday, September 30, 2016

Feds Testing Zika Vaccine : newsmax





As it stated in newsmax

Feds Testing Zika Vaccine

Feds Testing Zika Vaccine
Feds Testing Zika Vaccine
The war against the Zika virus has a new front — a vaccine developed by the National Institutes for Health has entered Phase I clinical trials.Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH developed the vaccine, which does not contain the Zika virus, according to The Journal of the American Medical Association.It is based on an altered DNA strand that prompts an immune response against the virus, and has shown strong promise in animal testing.


besides seeker

Zika Linked to Head Defects as Vaccine Money OK'd

Zika Linked to Head Defects as Vaccine Money OK'd
Zika Linked to Head Defects as Vaccine Money OK'd
Photo: Aedes aegypti mosquitoes are seen at the Laboratory of Entomology and Ecology of the Dengue Branch of the U.S. Centers for Disease Control and Prevention in San Juan, Puerto Rico.REUTERS/Alvin Baez/File PhotoFederal health officials studying how to stop Zika are breathing a bit easier today after Congress finally passed long-overdue funding for vaccine clinical trials next year.At the same time, medical researchers in California announced today they have found how the Zika virus disrupts the skull and face of developing babies.


in addition jamanetwork

Zika Vaccine Enters Clinical Trials

Zika Vaccine Enters Clinical Trials
Zika Vaccine Enters Clinical Trials
Also Meets CME requirements for:Accreditation InformationThe American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course.Physicians should claim only the credit commensurate with the extent of their participation in the activity.


No comments:

Post a Comment